Clinical Trials Logo
  1. Home
  2. Cocaine-Related Disorders
  3. NCT00000280
  4. Details
NCT00000280 Clinical Trial

Glutaminergic Agents for Cocaine Abuse - 5

Cocaine-Related Disorders Clinical Trial

Official title:
Glutaminergic Agents for Cocaine Abuse

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00000280
Other study ID # NIDA-09250-5
Secondary ID P50DA009250P50-0
Status Completed
Phase Phase 1
First received September 20, 1999
Last updated April 21, 2017
Start date September 1994
Est. completion date August 1999

Study information
Verified date December 2002
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate glutaminergic agents for cocaine abuse.

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date August 1999
Est. primary completion date August 1999
Accepts healthy volunteers No
Gender All
Age group 18 Years to 45 Years
Eligibility Please contact site for information.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Nimodipine

Locations
Country Name City State
United States VA Connecticut Healthcare System New Haven Connecticut

Sponsors (3)
Lead Sponsor Collaborator
Yale University National Institute on Drug Abuse (NIDA), VA Connecticut Healthcare System

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Cocaine effects
See also
  Status Clinical Trial Phase
Completed NCT01526538 - Improving Learning-based Treatment of Cocaine Dependence With Medication Phase 2
Completed NCT00877435 - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial N/A
Completed NCT00430690 - Acoustic Startle Reduction In Cocaine Dependence
Completed NCT00217997 - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals N/A
Active, not recruiting NCT00094315 - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1 Phase 1
Terminated NCT00142883 - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 N/A
Completed NCT00218348 - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Phase 2
Completed NCT00142844 - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 Phase 2
Completed NCT00158132 - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2 Phase 2
Completed NCT00000294 - Effects of Carvedilol on Cocaine Use in Humans - 11 Phase 2
Completed NCT00015054 - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Phase 2
Completed NCT00000308 - Dextroamphetamine-Cocaine Behavioral Intervention - 5 Phase 2
Terminated NCT00000276 - Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Phase 1
Completed NCT00000278 - Disulfiram for Cocaine-Alcohol Abuse - 3 Phase 2
Completed NCT00000282 - Pemoline for Cocaine Abuse - 7 Phase 2
Completed NCT00000281 - Pharmacotherapy for Schizophrenic Drug Users - 6 Phase 2
Completed NCT00000306 - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Phase 2
Completed NCT00000314 - M-CPP and Fenfluramine in Cocaine Addicts - 3 Phase 2
Completed NCT00000188 - Selegiline in Treatment of Cocaine Dependence - 2 Phase 2
Completed NCT00000277 - Mazindol for Cocaine Abuse - 2 Phase 2